A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Pfizer
Mayo Clinic
Canadian Cancer Trials Group
American College of Radiology Imaging Network
Centro Nacional de Investigaciones Oncologicas CARLOS III
City of Hope Medical Center
NYU Langone Health